期刊文献+

丹参多酚对慢性阻塞性肺疾病急性加重期肺动脉压及D-二聚体的影响 被引量:1

Influence of salvianolate on AECOPD pulmonary artery pressure and D-dimer
下载PDF
导出
摘要 目的:探讨丹参多酚注射液对慢性阻塞性肺疾病急性加重期肺动脉压及D-二聚体的影响。方法:40例符合诊断标准的AECOPD患者被随机分为对照组和治疗组,两组均接受COPD诊治指南推荐的抗感染、化痰、平喘、吸氧等治疗,治疗组在上述治疗的基础上与丹参多酚200mg/d,静脉滴注,两组疗程均为14d,治疗前后分别测定肺动脉压及D-二聚体,对其结果进行统计学分析。结果:治疗前两组AECOPD患者D-二聚体水平均高于正常参考值上限,治疗后两组肺动脉压及D-二聚体水平均有下降,其中治疗组上述指标下降更为显著,治疗前后比较P<0.05;治疗后组间比较亦有显著性差异P<0.05。结论:丹参多酚注射液可改善AECOPD患者血液高凝状态,改善机体氧合功能,降低肺动脉压,有助于提高临床疗效。 Objective: To investigate the influence of salvianolate on COPD acute exacerbation pulmonary artery pressure and D-dimer. Methods: 40 patients with chronic obstructive pulmonary disease acute exacerbation (AECOPD) were randomly divided into control group and treated group. Both groups were accepted COPD treatment guidelines recommend anti-infection, phlegm, asthma, oxygen therapy etc. The treated group was given salvianolate 200mg/d, intravenous infusion more. The treatment lasted 14 days, before and after treatment pulmonary artery pressure and D-dimer were measured, the results were statistically analyzed. Results:Before treatment, patients with AECOPD D-dimer levels were higher than the upper limit of normal reference values, the two groups after the treatment pulmonary arterial pressure and D-dimer levels were decreased, in the treated group decreased more significantly above indicators, before and after treatment P〈0.05. Between the two groups showed significant differences P〈0.05. Conclusion:Salvianolate injection can improve AECOPD patients with hypercoagulable states, improve the body’s oxygenation and reduce pulmonary artery pressure, helps to improve the clinical efficacy.
机构地区 江门市中心医院
出处 《中医临床研究》 2014年第4期24-25,共2页 Clinical Journal Of Chinese Medicine
关键词 慢性阻塞性肺疾病 急性加重期 肺动脉压 D-二聚体 COPD Acute exacerbation Pulmonary artery pressure D-dimer
  • 相关文献

参考文献7

二级参考文献92

  • 1有创-无创序贯机械通气多中心研究协作组.以肺部感染控制窗为切换点行有创与无创序贯机械通气治疗慢性阻塞性肺疾病所致严重呼吸衰竭的随机对照研究[J].中华结核和呼吸杂志,2006,29(1):14-18. 被引量:279
  • 2慢性阻塞性肺疾病诊治指南(2007年修订版)[J].中华结核和呼吸杂志,2007,30(1):8-17. 被引量:8234
  • 3Mahler DA,Selecky PA,Harrod CG,et al.American College of Chest Physicians consensus statement on the management of dyspnea in patients with advanced lung or heart disease. Chest,2010,137:674-691.
  • 4Minai OA,Chaouat A,Adnot S. Pulmonary hypertension in COPD:epidemiology,significance,and management:pulmonary vascular disease:the global perspective. Chest,2010,137 (6Suppl):39S-51S.
  • 5Macnee W.Right heart function in COPD.Semin Respir Crit Care Med,2010,31:295-312.
  • 6Nussbaumer-Ochsner Y, Rabe KF. Systemic manifestations of COPD.Chest,2011,139:165-173.
  • 7Blanco I,Gimeno E,Munoz PA,et al. Hemodynamic and gas exchange effects of sildenafil in patients with chronic obstructive pulmonary disease and pulmonary hypertension.Am J Respir Crit Care Med,2010,181:270-278.
  • 8Barnes PJ.Theophylline in chronic obstructive pulmonary disease:new horizons.Proc Am Thorac Soc,2005,2:334-339.
  • 9Zheng JP,Kang J,Huang SG,et al.Effect of carbocisteine on acute exacerbation of chronic obstructive pulmonary disease (PEACE Study):a randomised placebo-controlled study.Lancet,2008,371:2013-2018.
  • 10Colice GL,Shafazand S,Griffin JP,et al.Physiologic evaluation of the patient with lung cancer being considered for resectional surgery:ACCP evidenced-based clinical practice guidelines (2nd edition).Chest,2007,132(3 Suppl):161S-177S.

共引文献8317

同被引文献18

引证文献1

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部